PURPOSE: To determine the efficacy of the addition of gefitinib to raltitrexed in patients with colorectal cancer (CRC) that have progressed after first line chemotherapy. The study also sought to explore the safety of the combination and to investigate biomarkers predictive outcome. METHODS: A total of 76 patients were randomized to raltitrexed (3 mg/m(2) i.v.) every 21 days plus either daily gefitinib (250 mg p.o.) or placebo. The primary endpoint of the study was progression free survival (PFS). Tumor tissues were collected to determine the expression of EGFR, pEGFR, pMAPK, and pAkt. RESULTS: Both groups were well balanced with regard to prognostic factors. Treatment was well tolerated with no increased in toxicity except diarrhea and skin rash in the combination group. There were no differences in PFS between the combination arm [63 days (95% CI: 57-84)] compared to the raltitrexed alone arm [72 days (95% CI: 59-132)], or overall survival 361 days (95% CI: 283-533 days) versus 291 days (95% CI: 255-539 days) respectively. The objective response rate was 7.9% (3 patients) (CI 95%: 1,66-21,38) versus 5.3% (2 patients) (CI 0,64-17,75), respectively. The biomarker studies were not conclusive. CONCLUSION: The combination of raltitrexed and gefitinib was well tolerated although was not associated with improved progression free survival in patients with refractory CRC.
RCT Entities:
PURPOSE: To determine the efficacy of the addition of gefitinib to raltitrexed in patients with colorectal cancer (CRC) that have progressed after first line chemotherapy. The study also sought to explore the safety of the combination and to investigate biomarkers predictive outcome. METHODS: A total of 76 patients were randomized to raltitrexed (3 mg/m(2) i.v.) every 21 days plus either daily gefitinib (250 mg p.o.) or placebo. The primary endpoint of the study was progression free survival (PFS). Tumor tissues were collected to determine the expression of EGFR, pEGFR, pMAPK, and pAkt. RESULTS: Both groups were well balanced with regard to prognostic factors. Treatment was well tolerated with no increased in toxicity except diarrhea and skin rash in the combination group. There were no differences in PFS between the combination arm [63 days (95% CI: 57-84)] compared to the raltitrexed alone arm [72 days (95% CI: 59-132)], or overall survival 361 days (95% CI: 283-533 days) versus 291 days (95% CI: 255-539 days) respectively. The objective response rate was 7.9% (3 patients) (CI 95%: 1,66-21,38) versus 5.3% (2 patients) (CI 0,64-17,75), respectively. The biomarker studies were not conclusive. CONCLUSION: The combination of raltitrexed and gefitinib was well tolerated although was not associated with improved progression free survival in patients with refractory CRC.
Authors: Timothy Kuo; Cheryl D Cho; Joanne Halsey; Heather A Wakelee; Ranjana H Advani; James M Ford; George A Fisher; Branimir I Sikic Journal: J Clin Oncol Date: 2005-08-20 Impact factor: 44.544
Authors: Mace L Rothenberg; Bonnie LaFleur; Donna E Levy; Mary Kay Washington; Sherry L Morgan-Meadows; Ramesh K Ramanathan; Jordan D Berlin; Al B Benson; Robert J Coffey Journal: J Clin Oncol Date: 2005-12-20 Impact factor: 44.544
Authors: F Ciardiello; R Caputo; R Bianco; V Damiano; G Pomatico; S De Placido; A R Bianco; G Tortora Journal: Clin Cancer Res Date: 2000-05 Impact factor: 12.531
Authors: E Van Cutsem; C Verslype; P Beale; S Clarke; R Bugat; A Rakhit; S H Fettner; U Brennscheidt; A Feyereislova; J-P Delord Journal: Ann Oncol Date: 2007-11-06 Impact factor: 32.976
Authors: P Rougier; E Van Cutsem; E Bajetta; N Niederle; K Possinger; R Labianca; M Navarro; R Morant; H Bleiberg; J Wils; L Awad; P Herait; C Jacques Journal: Lancet Date: 1998-10-31 Impact factor: 79.321
Authors: F Cappuzzo; G Finocchiaro; E Rossi; P A Jänne; C Carnaghi; C Calandri; K Bencardino; C Ligorio; F Ciardiello; T Pressiani; A Destro; M Roncalli; L Crino; W A Franklin; A Santoro; M Varella-Garcia Journal: Ann Oncol Date: 2007-10-31 Impact factor: 32.976
Authors: M L Veronese; W Sun; B Giantonio; J Berlin; J Shults; L Davis; D G Haller; P J O'Dwyer Journal: Br J Cancer Date: 2005-05-23 Impact factor: 7.640
Authors: Simone Mocellin; Zora Baretta; Marta Roqué I Figuls; Ivan Solà; Marta Martin-Richard; Sara Hallum; Xavier Bonfill Cosp Journal: Cochrane Database Syst Rev Date: 2017-01-27
Authors: Chiara Cremolini; Carlotta Antoniotti; Filippo Pietrantonio; Rosa Berenato; Marco Tampellini; Chiara Baratelli; Lisa Salvatore; Federica Marmorino; Beatrice Borelli; Federico Nichetti; Paolo Bironzo; Cristina Sonetto; Maria Di Bartolomeo; Filippo de Braud; Fotios Loupakis; Alfredo Falcone; M Di Maio Journal: Cancer Res Treat Date: 2016-11-15 Impact factor: 4.679